ResQ Pharma, Inc.
Glenview, IL · Founded 2015 · CIK 0001668333 · Medtech
Lipid emulsion infusion therapy to treat lipophilic drug toxicity
resqpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.4M
- 5 Form D · Dec 2024
- 21 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 4 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $325,000 | |
| Private capital raised | Form D · SEC | $739,500 | |
| Private capital raised | Form D · SEC | $1,020,000 | |
| Private capital raised | Form D · SEC | $205,501 | |
| Private capital raised | Form D · SEC | $99,999 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1072 | Circulogene Theranostics, Inc. | — | $9.1M |
| 1073 | Pepex Biomedical, Inc. | — | $202K |
| 1074 | Paradromics, Inc. | — | $55M |
| 1075 | ResQ Pharma, Inc. | — | $2.4M |
| 1076 | ZSX MEDICAL LLC | — | $1.1M |
| 1077 | Reflexion Pharmaceuticals, Inc. | — | $1.1M |
| 1078 | PathogenDx, Inc. | — | $675K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Todd BeckDirector · Executive Officer · Promoter
- David BowmanExecutive Officer
- Paul BurtonDirector · Executive Officer
- Steve BylinaDirector · Executive Officer · Promoter
- Antoinette GawinDirector · Executive Officer · Promoter
- Paul HertzDirector · Executive Officer · Promoter
- Dominic O'KeefeDirector · Executive Officer · Promoter
- Israel RubinsteinDirector
- August SchuppDirector · Executive Officer · Promoter
- Joel TuneDirector · Executive Officer · Promoter
- Guy WeinbergDirector · Executive Officer · Promoter
- Francis WisniewskiDirector · Executive Officer · Promoter
Patents
- Lipid Emulsions And Uses Thereofgranted
- Methods For Decreasing Injuries Associated With Intraoperative Hypotensiongranted
- Lipid Emulsions And Uses Thereofapplication
- Methods For Decreasing Injuries Associated With Intraoperative Hypotensiongranted
- Methods For Decreasing Injuries Associated With Intraoperative Hypotensiongranted
- Lipid Emulsions And Uses Thereofapplication
- Vitamin K-enriched Lipid Emulsion Formulations For The Treatment Of Pharma Toxicityapplication
- Pre-filled Syringe Kitapplication
- Lipid Emulsions And Uses Thereofapplication
- Methods For Decreasing Injuries Associated With Intraoperative Hypotensionapplication
- Methods For Decreasing Injuries Associated With Intraoperative Hypotensionapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.